Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Androgen suppression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Androgen suppression. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-000160-15 Sponsor Protocol Number: MVT-601-3201 Start Date*: 2017-07-25
    Sponsor Name:Myovant Sciences GmbH
    Full Title: HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
    Medical condition: Androgen-sensitive advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) SK (Completed) DK (Completed) FI (Completed) ES (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002100-42 Sponsor Protocol Number: ARD-0301-003 Start Date*: 2005-08-24
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formu...
    Medical condition: advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004094-25 Sponsor Protocol Number: EGD-EC-003 Start Date*: 2006-01-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who a...
    Medical condition: Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing ...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10060862 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) AT (Prematurely Ended) FI (Completed) SK (Completed) IE (Completed) HU (Completed) DE (Completed) ES (Completed) SE (Completed) GB (Completed) PT (Completed) BE (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005742-39 Sponsor Protocol Number: ARD-0301-008 Start Date*: 2006-02-01
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formu...
    Medical condition: ADVANCED PROSTATE CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005315-26 Sponsor Protocol Number: A25165 Start Date*: 2008-07-01
    Sponsor Name:CONRAD, Eastern Virgina Medical School
    Full Title: Sperm Suppression and Contraceptive Protection provived by Norethisterone Enantate (NET-EN) combined with Testosterone Undecanoate (TU) in healthy men.
    Medical condition: The proposed study is designed to evaluate whether the combination of a progestin, norethisterone enantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effective ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Temporarily Halted) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-002071-29 Sponsor Protocol Number: ITT012“ELISA” Start Date*: 2014-12-22
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA MEDICA USL8
    Full Title: A RANDOMIZED PROSPECTIVE MULTICENTRE PHASE II STUDY OF ANDROGEN DEPRIVATION THERAPY (ADT) PLUS RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN LOCALLY ADVANCED VERY HIGH-RISK PRO...
    Medical condition: LOCALLY ADVANCED VERY HIGH-RISK PROSTATE CANCER
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10029002 Neoplasm of the prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001790-25 Sponsor Protocol Number: FP01C-13-001 Start Date*: 2014-09-01
    Sponsor Name:Foresee Pharmaceuticals Co., Ltd.
    Full Title: An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma
    Medical condition: Advanced Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) SK (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005607-33 Sponsor Protocol Number: 411-IP-06-01-0000/IPSS-D039 Start Date*: 2008-02-08
    Sponsor Name:KOMINOX USA, Inc.
    Full Title: A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®)
    Medical condition: Prostate Cancer Metastatic
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003705-27 Sponsor Protocol Number: MK URO 4 Start Date*: 2007-09-27
    Sponsor Name:AKH Vienna
    Full Title: RANDOMIZED, CONTROLLED BIOMARKER STUDY EVALUATING THE ANTI-ANGIOGENIC ACTIVITY OF SUNITINIB IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS TREATED BY DOCETAXEL
    Medical condition: hormone refraktory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001648-64 Sponsor Protocol Number: No EP-24332T-A014 Start Date*: 2004-09-16
    Sponsor Name:ardana LTD
    Full Title: A Phase II multicentre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix 90 mg, long-acting f...
    Medical condition: advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000161-40 Sponsor Protocol Number: AdrenalClock Start Date*: 2022-07-18
    Sponsor Name:Medical University of Vienna, Division of Endocrinology
    Full Title: Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion
    Medical condition: Autonomous cortisol secretion in patients with adrenal adenoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005276-27 Sponsor Protocol Number: FE 200486 CS35 Start Date*: 2009-07-17
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Canc...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001650-77 Sponsor Protocol Number: FE200486 CS18 Start Date*: 2007-05-14
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring ...
    Medical condition: Patients with prostate cancer requiring androgen ablation therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004817-15 Sponsor Protocol Number: CTOO19099GZA Start Date*: 2020-03-12
    Sponsor Name:GZA vzw
    Full Title: A prospective, biomarker-based, clinical trial in patients with metastatic castration resistant prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006055-39 Sponsor Protocol Number: FE200486 CS26 Start Date*: 2008-01-30
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androge...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) FI (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002498-36 Sponsor Protocol Number: CCN017 Start Date*: 2018-10-12
    Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
    Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005822-23 Sponsor Protocol Number: REK231814 Start Date*: 2012-10-16
    Sponsor Name:Haukeland University Hospital
    Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA
    Medical condition: Congenital adrenal hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021011-16 Sponsor Protocol Number: OGX-011-11 Start Date*: 2010-09-27
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer
    Medical condition: metastatic castrate resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) FR (Completed) DE (Completed) ES (Completed) BE (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002271-17 Sponsor Protocol Number: 9785-CL-0410 Start Date*: 2014-02-25
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate
    Medical condition: Metastatic progressive castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003720-32 Sponsor Protocol Number: SPECTRE2015 Start Date*: 2016-06-01
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Oct 26 04:12:37 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA